No Data
No Data
Sarepta's Valuation Seen As An Easy Pill to Swallow -- Market Talk
J.P. Morgan Maintains Sarepta Therapeutics(SRPT.US) With Buy Rating
Analysts Offer Insights on Healthcare Companies: Sarepta Therapeutics (SRPT) and DocGo (DCGO)
Notable Analyst Calls This Week: Carvana, Devon Energy and Palantir Among Top Picks
Barclays Maintains Sarepta Therapeutics(SRPT.US) With Buy Rating, Maintains Target Price $209
Mizuho Securities Maintains Sarepta Therapeutics(SRPT.US) With Buy Rating
No Data
No Data